BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=590238, encodeId=8fae5902380a, content=24小时内接受了，果然是神刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=261, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0f52242192, createdName=12147f1dm17暂无昵称, createdTime=Tue May 05 00:00:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2188537, encodeId=4158218853e31, content=2024年2.18号晚上投稿，2.19号凌晨状态为submitted to journal，今天2.21号还是submitted to journal状态，编号为24-1364，希望能有个好结果吧，祈祷能赶上毕业！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73869177223, createdName=ms3000000806055068, createdTime=Wed Feb 21 17:36:20 CST 2024, time=2024-02-21, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2172975, encodeId=bbb521e297532, content=偏重的研究方向：分子生物学 经验分享：请问现在送审到多少号啦？我是7434<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=31, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231206/2dee05e08ca84fb09f8330013e8e418e/e2624ef6b4474dc8bf92c7e3eed5d474.jpg, createdBy=4de09089222, createdName=ms5000001058303842, createdTime=Tue Dec 05 09:17:45 CST 2023, time=2023-12-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2190215, encodeId=174121902152a, content=uu们，请问2024.1.14号投的稿子，到现在一直是 Transfer Pending过去了这么久了，是不是要被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231207/d8ac6ae0bc4f46eb96530f032af93ce5/c7bf7aa943884522a9b566a5d00e8e79.jpg, createdBy=8beb8373299, createdName=是周树人非鲁迅, createdTime=Thu Feb 29 22:28:30 CST 2024, time=2024-02-29, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2187626, encodeId=3721218e626e6, content=投稿命中率:50.0 偏重的研究方向：乳酸化修饰;胃癌 经验分享：记录一下：2024年2月14 Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11f06507596, createdName=ms9000001327347856, createdTime=Fri Feb 16 10:32:22 CST 2024, time=2024-02-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2187904, encodeId=fb10218e90466, content=偏重的研究方向：肿瘤;干细胞 经验分享：小tips：这个期刊极其喜欢建议转投爱思唯尔旗下的bbr和hy两本杂志。千万千万别转投，这是为了提高这两本杂志投稿率才建议你转投的。转投一不会优先审稿二仍然需要自己网站操作。最难绷的是拒稿也很慢。。。拖拖拉拉一到两个月给你拒掉。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca8184855, createdName=ms6000000187674201, createdTime=Sun Feb 18 10:26:17 CST 2024, time=2024-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2110247, encodeId=e1b7211024e24, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：9天就接收了，从1月5号提交到1月14号，直接接收。这速度，神了，不禁感叹，神刊！！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bc56291844, createdName=3709443_9392, createdTime=Sat Jan 14 22:35:24 CST 2023, time=2023-01-14, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2153304, encodeId=b34c21533047f, content=请教各位，under review 快三周了，时间一直在变，但状态没变，这是什么情况有小伙伴知道不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b215411313, createdName=ms1000001079311439, createdTime=Thu Aug 17 21:43:03 CST 2023, time=2023-08-17, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2152251, encodeId=57672152251aa, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：分享一下投稿经验：7.25号Submitted to journal，7.28 内审，8.3 送外审，可以在**中跟踪到有多少审稿人，也可以看到有没有审稿人返稿，目前8月11日还没有审稿人返稿，等待后续，投的article。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6faa8350887, createdName=ms7000001902667042, createdTime=Fri Aug 11 12:45:13 CST 2023, time=2023-08-11, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2170081, encodeId=a92721e00814e, content=偏重的研究方向：microRNA 经验分享：稿件7186，润色提交，WB整膜三重复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd069039656, createdName=ms6000000198285398, createdTime=Tue Nov 21 21:51:38 CST 2023, time=2023-11-21, status=1, ipAttribution=贵州省)]

2020-05-05 12147f1dm17暂无昵称

24小时内接受了，果然是神刊！

261 26

展开26条回复

[GetPortalCommentsPageByObjectIdResponse(id=590238, encodeId=8fae5902380a, content=24小时内接受了，果然是神刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=261, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0f52242192, createdName=12147f1dm17暂无昵称, createdTime=Tue May 05 00:00:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2188537, encodeId=4158218853e31, content=2024年2.18号晚上投稿，2.19号凌晨状态为submitted to journal，今天2.21号还是submitted to journal状态，编号为24-1364，希望能有个好结果吧，祈祷能赶上毕业！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73869177223, createdName=ms3000000806055068, createdTime=Wed Feb 21 17:36:20 CST 2024, time=2024-02-21, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2172975, encodeId=bbb521e297532, content=偏重的研究方向：分子生物学 经验分享：请问现在送审到多少号啦？我是7434<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=31, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231206/2dee05e08ca84fb09f8330013e8e418e/e2624ef6b4474dc8bf92c7e3eed5d474.jpg, createdBy=4de09089222, createdName=ms5000001058303842, createdTime=Tue Dec 05 09:17:45 CST 2023, time=2023-12-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2190215, encodeId=174121902152a, content=uu们，请问2024.1.14号投的稿子，到现在一直是 Transfer Pending过去了这么久了，是不是要被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231207/d8ac6ae0bc4f46eb96530f032af93ce5/c7bf7aa943884522a9b566a5d00e8e79.jpg, createdBy=8beb8373299, createdName=是周树人非鲁迅, createdTime=Thu Feb 29 22:28:30 CST 2024, time=2024-02-29, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2187626, encodeId=3721218e626e6, content=投稿命中率:50.0 偏重的研究方向：乳酸化修饰;胃癌 经验分享：记录一下：2024年2月14 Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11f06507596, createdName=ms9000001327347856, createdTime=Fri Feb 16 10:32:22 CST 2024, time=2024-02-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2187904, encodeId=fb10218e90466, content=偏重的研究方向：肿瘤;干细胞 经验分享：小tips：这个期刊极其喜欢建议转投爱思唯尔旗下的bbr和hy两本杂志。千万千万别转投，这是为了提高这两本杂志投稿率才建议你转投的。转投一不会优先审稿二仍然需要自己网站操作。最难绷的是拒稿也很慢。。。拖拖拉拉一到两个月给你拒掉。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca8184855, createdName=ms6000000187674201, createdTime=Sun Feb 18 10:26:17 CST 2024, time=2024-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2110247, encodeId=e1b7211024e24, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：9天就接收了，从1月5号提交到1月14号，直接接收。这速度，神了，不禁感叹，神刊！！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bc56291844, createdName=3709443_9392, createdTime=Sat Jan 14 22:35:24 CST 2023, time=2023-01-14, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2153304, encodeId=b34c21533047f, content=请教各位，under review 快三周了，时间一直在变，但状态没变，这是什么情况有小伙伴知道不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b215411313, createdName=ms1000001079311439, createdTime=Thu Aug 17 21:43:03 CST 2023, time=2023-08-17, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2152251, encodeId=57672152251aa, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：分享一下投稿经验：7.25号Submitted to journal，7.28 内审，8.3 送外审，可以在**中跟踪到有多少审稿人，也可以看到有没有审稿人返稿，目前8月11日还没有审稿人返稿，等待后续，投的article。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6faa8350887, createdName=ms7000001902667042, createdTime=Fri Aug 11 12:45:13 CST 2023, time=2023-08-11, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2170081, encodeId=a92721e00814e, content=偏重的研究方向：microRNA 经验分享：稿件7186，润色提交，WB整膜三重复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd069039656, createdName=ms6000000198285398, createdTime=Tue Nov 21 21:51:38 CST 2023, time=2023-11-21, status=1, ipAttribution=贵州省)]

2024-02-21 ms3000000806055068 来自四川省

2024年2.18号晚上投稿，2.19号凌晨状态为submitted to journal，今天2.21号还是submitted to journal状态，编号为24-1364，希望能有个好结果吧，祈祷能赶上毕业！

19 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=590238, encodeId=8fae5902380a, content=24小时内接受了，果然是神刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=261, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0f52242192, createdName=12147f1dm17暂无昵称, createdTime=Tue May 05 00:00:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2188537, encodeId=4158218853e31, content=2024年2.18号晚上投稿，2.19号凌晨状态为submitted to journal，今天2.21号还是submitted to journal状态，编号为24-1364，希望能有个好结果吧，祈祷能赶上毕业！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73869177223, createdName=ms3000000806055068, createdTime=Wed Feb 21 17:36:20 CST 2024, time=2024-02-21, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2172975, encodeId=bbb521e297532, content=偏重的研究方向：分子生物学 经验分享：请问现在送审到多少号啦？我是7434<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=31, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231206/2dee05e08ca84fb09f8330013e8e418e/e2624ef6b4474dc8bf92c7e3eed5d474.jpg, createdBy=4de09089222, createdName=ms5000001058303842, createdTime=Tue Dec 05 09:17:45 CST 2023, time=2023-12-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2190215, encodeId=174121902152a, content=uu们，请问2024.1.14号投的稿子，到现在一直是 Transfer Pending过去了这么久了，是不是要被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231207/d8ac6ae0bc4f46eb96530f032af93ce5/c7bf7aa943884522a9b566a5d00e8e79.jpg, createdBy=8beb8373299, createdName=是周树人非鲁迅, createdTime=Thu Feb 29 22:28:30 CST 2024, time=2024-02-29, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2187626, encodeId=3721218e626e6, content=投稿命中率:50.0 偏重的研究方向：乳酸化修饰;胃癌 经验分享：记录一下：2024年2月14 Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11f06507596, createdName=ms9000001327347856, createdTime=Fri Feb 16 10:32:22 CST 2024, time=2024-02-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2187904, encodeId=fb10218e90466, content=偏重的研究方向：肿瘤;干细胞 经验分享：小tips：这个期刊极其喜欢建议转投爱思唯尔旗下的bbr和hy两本杂志。千万千万别转投，这是为了提高这两本杂志投稿率才建议你转投的。转投一不会优先审稿二仍然需要自己网站操作。最难绷的是拒稿也很慢。。。拖拖拉拉一到两个月给你拒掉。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca8184855, createdName=ms6000000187674201, createdTime=Sun Feb 18 10:26:17 CST 2024, time=2024-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2110247, encodeId=e1b7211024e24, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：9天就接收了，从1月5号提交到1月14号，直接接收。这速度，神了，不禁感叹，神刊！！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bc56291844, createdName=3709443_9392, createdTime=Sat Jan 14 22:35:24 CST 2023, time=2023-01-14, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2153304, encodeId=b34c21533047f, content=请教各位，under review 快三周了，时间一直在变，但状态没变，这是什么情况有小伙伴知道不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b215411313, createdName=ms1000001079311439, createdTime=Thu Aug 17 21:43:03 CST 2023, time=2023-08-17, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2152251, encodeId=57672152251aa, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：分享一下投稿经验：7.25号Submitted to journal，7.28 内审，8.3 送外审，可以在**中跟踪到有多少审稿人，也可以看到有没有审稿人返稿，目前8月11日还没有审稿人返稿，等待后续，投的article。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6faa8350887, createdName=ms7000001902667042, createdTime=Fri Aug 11 12:45:13 CST 2023, time=2023-08-11, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2170081, encodeId=a92721e00814e, content=偏重的研究方向：microRNA 经验分享：稿件7186，润色提交，WB整膜三重复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd069039656, createdName=ms6000000198285398, createdTime=Tue Nov 21 21:51:38 CST 2023, time=2023-11-21, status=1, ipAttribution=贵州省)]

2023-12-05 ms5000001058303842 来自北京

偏重的研究方向：分子生物学
经验分享：请问现在送审到多少号啦？我是7434#期刊论坛#

69 31

展开31条回复

[GetPortalCommentsPageByObjectIdResponse(id=590238, encodeId=8fae5902380a, content=24小时内接受了，果然是神刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=261, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0f52242192, createdName=12147f1dm17暂无昵称, createdTime=Tue May 05 00:00:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2188537, encodeId=4158218853e31, content=2024年2.18号晚上投稿，2.19号凌晨状态为submitted to journal，今天2.21号还是submitted to journal状态，编号为24-1364，希望能有个好结果吧，祈祷能赶上毕业！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73869177223, createdName=ms3000000806055068, createdTime=Wed Feb 21 17:36:20 CST 2024, time=2024-02-21, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2172975, encodeId=bbb521e297532, content=偏重的研究方向：分子生物学 经验分享：请问现在送审到多少号啦？我是7434<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=31, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231206/2dee05e08ca84fb09f8330013e8e418e/e2624ef6b4474dc8bf92c7e3eed5d474.jpg, createdBy=4de09089222, createdName=ms5000001058303842, createdTime=Tue Dec 05 09:17:45 CST 2023, time=2023-12-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2190215, encodeId=174121902152a, content=uu们，请问2024.1.14号投的稿子，到现在一直是 Transfer Pending过去了这么久了，是不是要被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231207/d8ac6ae0bc4f46eb96530f032af93ce5/c7bf7aa943884522a9b566a5d00e8e79.jpg, createdBy=8beb8373299, createdName=是周树人非鲁迅, createdTime=Thu Feb 29 22:28:30 CST 2024, time=2024-02-29, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2187626, encodeId=3721218e626e6, content=投稿命中率:50.0 偏重的研究方向：乳酸化修饰;胃癌 经验分享：记录一下：2024年2月14 Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11f06507596, createdName=ms9000001327347856, createdTime=Fri Feb 16 10:32:22 CST 2024, time=2024-02-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2187904, encodeId=fb10218e90466, content=偏重的研究方向：肿瘤;干细胞 经验分享：小tips：这个期刊极其喜欢建议转投爱思唯尔旗下的bbr和hy两本杂志。千万千万别转投，这是为了提高这两本杂志投稿率才建议你转投的。转投一不会优先审稿二仍然需要自己网站操作。最难绷的是拒稿也很慢。。。拖拖拉拉一到两个月给你拒掉。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca8184855, createdName=ms6000000187674201, createdTime=Sun Feb 18 10:26:17 CST 2024, time=2024-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2110247, encodeId=e1b7211024e24, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：9天就接收了，从1月5号提交到1月14号，直接接收。这速度，神了，不禁感叹，神刊！！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bc56291844, createdName=3709443_9392, createdTime=Sat Jan 14 22:35:24 CST 2023, time=2023-01-14, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2153304, encodeId=b34c21533047f, content=请教各位，under review 快三周了，时间一直在变，但状态没变，这是什么情况有小伙伴知道不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b215411313, createdName=ms1000001079311439, createdTime=Thu Aug 17 21:43:03 CST 2023, time=2023-08-17, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2152251, encodeId=57672152251aa, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：分享一下投稿经验：7.25号Submitted to journal，7.28 内审，8.3 送外审，可以在**中跟踪到有多少审稿人，也可以看到有没有审稿人返稿，目前8月11日还没有审稿人返稿，等待后续，投的article。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6faa8350887, createdName=ms7000001902667042, createdTime=Fri Aug 11 12:45:13 CST 2023, time=2023-08-11, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2170081, encodeId=a92721e00814e, content=偏重的研究方向：microRNA 经验分享：稿件7186，润色提交，WB整膜三重复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd069039656, createdName=ms6000000198285398, createdTime=Tue Nov 21 21:51:38 CST 2023, time=2023-11-21, status=1, ipAttribution=贵州省)]

2024-02-29 是周树人非鲁迅来自湖南省

uu们，请问2024.1.14号投的稿子，到现在一直是 Transfer Pending过去了这么久了，是不是要被拒了

13 0

[GetPortalCommentsPageByObjectIdResponse(id=590238, encodeId=8fae5902380a, content=24小时内接受了，果然是神刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=261, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0f52242192, createdName=12147f1dm17暂无昵称, createdTime=Tue May 05 00:00:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2188537, encodeId=4158218853e31, content=2024年2.18号晚上投稿，2.19号凌晨状态为submitted to journal，今天2.21号还是submitted to journal状态，编号为24-1364，希望能有个好结果吧，祈祷能赶上毕业！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73869177223, createdName=ms3000000806055068, createdTime=Wed Feb 21 17:36:20 CST 2024, time=2024-02-21, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2172975, encodeId=bbb521e297532, content=偏重的研究方向：分子生物学 经验分享：请问现在送审到多少号啦？我是7434<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=31, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231206/2dee05e08ca84fb09f8330013e8e418e/e2624ef6b4474dc8bf92c7e3eed5d474.jpg, createdBy=4de09089222, createdName=ms5000001058303842, createdTime=Tue Dec 05 09:17:45 CST 2023, time=2023-12-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2190215, encodeId=174121902152a, content=uu们，请问2024.1.14号投的稿子，到现在一直是 Transfer Pending过去了这么久了，是不是要被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231207/d8ac6ae0bc4f46eb96530f032af93ce5/c7bf7aa943884522a9b566a5d00e8e79.jpg, createdBy=8beb8373299, createdName=是周树人非鲁迅, createdTime=Thu Feb 29 22:28:30 CST 2024, time=2024-02-29, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2187626, encodeId=3721218e626e6, content=投稿命中率:50.0 偏重的研究方向：乳酸化修饰;胃癌 经验分享：记录一下：2024年2月14 Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11f06507596, createdName=ms9000001327347856, createdTime=Fri Feb 16 10:32:22 CST 2024, time=2024-02-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2187904, encodeId=fb10218e90466, content=偏重的研究方向：肿瘤;干细胞 经验分享：小tips：这个期刊极其喜欢建议转投爱思唯尔旗下的bbr和hy两本杂志。千万千万别转投，这是为了提高这两本杂志投稿率才建议你转投的。转投一不会优先审稿二仍然需要自己网站操作。最难绷的是拒稿也很慢。。。拖拖拉拉一到两个月给你拒掉。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca8184855, createdName=ms6000000187674201, createdTime=Sun Feb 18 10:26:17 CST 2024, time=2024-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2110247, encodeId=e1b7211024e24, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：9天就接收了，从1月5号提交到1月14号，直接接收。这速度，神了，不禁感叹，神刊！！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bc56291844, createdName=3709443_9392, createdTime=Sat Jan 14 22:35:24 CST 2023, time=2023-01-14, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2153304, encodeId=b34c21533047f, content=请教各位，under review 快三周了，时间一直在变，但状态没变，这是什么情况有小伙伴知道不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b215411313, createdName=ms1000001079311439, createdTime=Thu Aug 17 21:43:03 CST 2023, time=2023-08-17, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2152251, encodeId=57672152251aa, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：分享一下投稿经验：7.25号Submitted to journal，7.28 内审，8.3 送外审，可以在**中跟踪到有多少审稿人，也可以看到有没有审稿人返稿，目前8月11日还没有审稿人返稿，等待后续，投的article。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6faa8350887, createdName=ms7000001902667042, createdTime=Fri Aug 11 12:45:13 CST 2023, time=2023-08-11, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2170081, encodeId=a92721e00814e, content=偏重的研究方向：microRNA 经验分享：稿件7186，润色提交，WB整膜三重复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd069039656, createdName=ms6000000198285398, createdTime=Tue Nov 21 21:51:38 CST 2023, time=2023-11-21, status=1, ipAttribution=贵州省)]

2024-02-16 ms9000001327347856 来自江苏省

投稿命中率:50.0
偏重的研究方向：乳酸化修饰;胃癌
经验分享：记录一下：2024年2月14 Submitted to Journal

14 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=590238, encodeId=8fae5902380a, content=24小时内接受了，果然是神刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=261, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0f52242192, createdName=12147f1dm17暂无昵称, createdTime=Tue May 05 00:00:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2188537, encodeId=4158218853e31, content=2024年2.18号晚上投稿，2.19号凌晨状态为submitted to journal，今天2.21号还是submitted to journal状态，编号为24-1364，希望能有个好结果吧，祈祷能赶上毕业！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73869177223, createdName=ms3000000806055068, createdTime=Wed Feb 21 17:36:20 CST 2024, time=2024-02-21, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2172975, encodeId=bbb521e297532, content=偏重的研究方向：分子生物学 经验分享：请问现在送审到多少号啦？我是7434<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=31, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231206/2dee05e08ca84fb09f8330013e8e418e/e2624ef6b4474dc8bf92c7e3eed5d474.jpg, createdBy=4de09089222, createdName=ms5000001058303842, createdTime=Tue Dec 05 09:17:45 CST 2023, time=2023-12-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2190215, encodeId=174121902152a, content=uu们，请问2024.1.14号投的稿子，到现在一直是 Transfer Pending过去了这么久了，是不是要被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231207/d8ac6ae0bc4f46eb96530f032af93ce5/c7bf7aa943884522a9b566a5d00e8e79.jpg, createdBy=8beb8373299, createdName=是周树人非鲁迅, createdTime=Thu Feb 29 22:28:30 CST 2024, time=2024-02-29, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2187626, encodeId=3721218e626e6, content=投稿命中率:50.0 偏重的研究方向：乳酸化修饰;胃癌 经验分享：记录一下：2024年2月14 Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11f06507596, createdName=ms9000001327347856, createdTime=Fri Feb 16 10:32:22 CST 2024, time=2024-02-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2187904, encodeId=fb10218e90466, content=偏重的研究方向：肿瘤;干细胞 经验分享：小tips：这个期刊极其喜欢建议转投爱思唯尔旗下的bbr和hy两本杂志。千万千万别转投，这是为了提高这两本杂志投稿率才建议你转投的。转投一不会优先审稿二仍然需要自己网站操作。最难绷的是拒稿也很慢。。。拖拖拉拉一到两个月给你拒掉。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca8184855, createdName=ms6000000187674201, createdTime=Sun Feb 18 10:26:17 CST 2024, time=2024-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2110247, encodeId=e1b7211024e24, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：9天就接收了，从1月5号提交到1月14号，直接接收。这速度，神了，不禁感叹，神刊！！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bc56291844, createdName=3709443_9392, createdTime=Sat Jan 14 22:35:24 CST 2023, time=2023-01-14, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2153304, encodeId=b34c21533047f, content=请教各位，under review 快三周了，时间一直在变，但状态没变，这是什么情况有小伙伴知道不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b215411313, createdName=ms1000001079311439, createdTime=Thu Aug 17 21:43:03 CST 2023, time=2023-08-17, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2152251, encodeId=57672152251aa, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：分享一下投稿经验：7.25号Submitted to journal，7.28 内审，8.3 送外审，可以在**中跟踪到有多少审稿人，也可以看到有没有审稿人返稿，目前8月11日还没有审稿人返稿，等待后续，投的article。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6faa8350887, createdName=ms7000001902667042, createdTime=Fri Aug 11 12:45:13 CST 2023, time=2023-08-11, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2170081, encodeId=a92721e00814e, content=偏重的研究方向：microRNA 经验分享：稿件7186，润色提交，WB整膜三重复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd069039656, createdName=ms6000000198285398, createdTime=Tue Nov 21 21:51:38 CST 2023, time=2023-11-21, status=1, ipAttribution=贵州省)]

2024-02-18 ms6000000187674201 来自上海

偏重的研究方向：肿瘤;干细胞
经验分享：小tips：这个期刊极其喜欢建议转投爱思唯尔旗下的bbr和hy两本杂志。千万千万别转投，这是为了提高这两本杂志投稿率才建议你转投的。转投一不会优先审稿二仍然需要自己网站操作。最难绷的是拒稿也很慢。。。拖拖拉拉一到两个月给你拒掉。

17 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=590238, encodeId=8fae5902380a, content=24小时内接受了，果然是神刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=261, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0f52242192, createdName=12147f1dm17暂无昵称, createdTime=Tue May 05 00:00:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2188537, encodeId=4158218853e31, content=2024年2.18号晚上投稿，2.19号凌晨状态为submitted to journal，今天2.21号还是submitted to journal状态，编号为24-1364，希望能有个好结果吧，祈祷能赶上毕业！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73869177223, createdName=ms3000000806055068, createdTime=Wed Feb 21 17:36:20 CST 2024, time=2024-02-21, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2172975, encodeId=bbb521e297532, content=偏重的研究方向：分子生物学 经验分享：请问现在送审到多少号啦？我是7434<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=31, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231206/2dee05e08ca84fb09f8330013e8e418e/e2624ef6b4474dc8bf92c7e3eed5d474.jpg, createdBy=4de09089222, createdName=ms5000001058303842, createdTime=Tue Dec 05 09:17:45 CST 2023, time=2023-12-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2190215, encodeId=174121902152a, content=uu们，请问2024.1.14号投的稿子，到现在一直是 Transfer Pending过去了这么久了，是不是要被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231207/d8ac6ae0bc4f46eb96530f032af93ce5/c7bf7aa943884522a9b566a5d00e8e79.jpg, createdBy=8beb8373299, createdName=是周树人非鲁迅, createdTime=Thu Feb 29 22:28:30 CST 2024, time=2024-02-29, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2187626, encodeId=3721218e626e6, content=投稿命中率:50.0 偏重的研究方向：乳酸化修饰;胃癌 经验分享：记录一下：2024年2月14 Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11f06507596, createdName=ms9000001327347856, createdTime=Fri Feb 16 10:32:22 CST 2024, time=2024-02-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2187904, encodeId=fb10218e90466, content=偏重的研究方向：肿瘤;干细胞 经验分享：小tips：这个期刊极其喜欢建议转投爱思唯尔旗下的bbr和hy两本杂志。千万千万别转投，这是为了提高这两本杂志投稿率才建议你转投的。转投一不会优先审稿二仍然需要自己网站操作。最难绷的是拒稿也很慢。。。拖拖拉拉一到两个月给你拒掉。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca8184855, createdName=ms6000000187674201, createdTime=Sun Feb 18 10:26:17 CST 2024, time=2024-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2110247, encodeId=e1b7211024e24, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：9天就接收了，从1月5号提交到1月14号，直接接收。这速度，神了，不禁感叹，神刊！！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bc56291844, createdName=3709443_9392, createdTime=Sat Jan 14 22:35:24 CST 2023, time=2023-01-14, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2153304, encodeId=b34c21533047f, content=请教各位，under review 快三周了，时间一直在变，但状态没变，这是什么情况有小伙伴知道不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b215411313, createdName=ms1000001079311439, createdTime=Thu Aug 17 21:43:03 CST 2023, time=2023-08-17, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2152251, encodeId=57672152251aa, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：分享一下投稿经验：7.25号Submitted to journal，7.28 内审，8.3 送外审，可以在**中跟踪到有多少审稿人，也可以看到有没有审稿人返稿，目前8月11日还没有审稿人返稿，等待后续，投的article。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6faa8350887, createdName=ms7000001902667042, createdTime=Fri Aug 11 12:45:13 CST 2023, time=2023-08-11, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2170081, encodeId=a92721e00814e, content=偏重的研究方向：microRNA 经验分享：稿件7186，润色提交，WB整膜三重复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd069039656, createdName=ms6000000198285398, createdTime=Tue Nov 21 21:51:38 CST 2023, time=2023-11-21, status=1, ipAttribution=贵州省)]

2023-01-14 3709443_9392 来自河北省

审稿速度:1.0 | 投稿命中率:95.0
经验分享：9天就接收了，从1月5号提交到1月14号，直接接收。这速度，神了，不禁感叹，神刊！！！！

84 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=590238, encodeId=8fae5902380a, content=24小时内接受了，果然是神刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=261, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0f52242192, createdName=12147f1dm17暂无昵称, createdTime=Tue May 05 00:00:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2188537, encodeId=4158218853e31, content=2024年2.18号晚上投稿，2.19号凌晨状态为submitted to journal，今天2.21号还是submitted to journal状态，编号为24-1364，希望能有个好结果吧，祈祷能赶上毕业！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73869177223, createdName=ms3000000806055068, createdTime=Wed Feb 21 17:36:20 CST 2024, time=2024-02-21, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2172975, encodeId=bbb521e297532, content=偏重的研究方向：分子生物学 经验分享：请问现在送审到多少号啦？我是7434<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=31, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231206/2dee05e08ca84fb09f8330013e8e418e/e2624ef6b4474dc8bf92c7e3eed5d474.jpg, createdBy=4de09089222, createdName=ms5000001058303842, createdTime=Tue Dec 05 09:17:45 CST 2023, time=2023-12-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2190215, encodeId=174121902152a, content=uu们，请问2024.1.14号投的稿子，到现在一直是 Transfer Pending过去了这么久了，是不是要被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231207/d8ac6ae0bc4f46eb96530f032af93ce5/c7bf7aa943884522a9b566a5d00e8e79.jpg, createdBy=8beb8373299, createdName=是周树人非鲁迅, createdTime=Thu Feb 29 22:28:30 CST 2024, time=2024-02-29, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2187626, encodeId=3721218e626e6, content=投稿命中率:50.0 偏重的研究方向：乳酸化修饰;胃癌 经验分享：记录一下：2024年2月14 Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11f06507596, createdName=ms9000001327347856, createdTime=Fri Feb 16 10:32:22 CST 2024, time=2024-02-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2187904, encodeId=fb10218e90466, content=偏重的研究方向：肿瘤;干细胞 经验分享：小tips：这个期刊极其喜欢建议转投爱思唯尔旗下的bbr和hy两本杂志。千万千万别转投，这是为了提高这两本杂志投稿率才建议你转投的。转投一不会优先审稿二仍然需要自己网站操作。最难绷的是拒稿也很慢。。。拖拖拉拉一到两个月给你拒掉。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca8184855, createdName=ms6000000187674201, createdTime=Sun Feb 18 10:26:17 CST 2024, time=2024-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2110247, encodeId=e1b7211024e24, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：9天就接收了，从1月5号提交到1月14号，直接接收。这速度，神了，不禁感叹，神刊！！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bc56291844, createdName=3709443_9392, createdTime=Sat Jan 14 22:35:24 CST 2023, time=2023-01-14, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2153304, encodeId=b34c21533047f, content=请教各位，under review 快三周了，时间一直在变，但状态没变，这是什么情况有小伙伴知道不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b215411313, createdName=ms1000001079311439, createdTime=Thu Aug 17 21:43:03 CST 2023, time=2023-08-17, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2152251, encodeId=57672152251aa, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：分享一下投稿经验：7.25号Submitted to journal，7.28 内审，8.3 送外审，可以在**中跟踪到有多少审稿人，也可以看到有没有审稿人返稿，目前8月11日还没有审稿人返稿，等待后续，投的article。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6faa8350887, createdName=ms7000001902667042, createdTime=Fri Aug 11 12:45:13 CST 2023, time=2023-08-11, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2170081, encodeId=a92721e00814e, content=偏重的研究方向：microRNA 经验分享：稿件7186，润色提交，WB整膜三重复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd069039656, createdName=ms6000000198285398, createdTime=Tue Nov 21 21:51:38 CST 2023, time=2023-11-21, status=1, ipAttribution=贵州省)]

2023-08-17 ms1000001079311439 来自贵州省

请教各位，under review 快三周了，时间一直在变，但状态没变，这是什么情况有小伙伴知道不

142 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=590238, encodeId=8fae5902380a, content=24小时内接受了，果然是神刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=261, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0f52242192, createdName=12147f1dm17暂无昵称, createdTime=Tue May 05 00:00:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2188537, encodeId=4158218853e31, content=2024年2.18号晚上投稿，2.19号凌晨状态为submitted to journal，今天2.21号还是submitted to journal状态，编号为24-1364，希望能有个好结果吧，祈祷能赶上毕业！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73869177223, createdName=ms3000000806055068, createdTime=Wed Feb 21 17:36:20 CST 2024, time=2024-02-21, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2172975, encodeId=bbb521e297532, content=偏重的研究方向：分子生物学 经验分享：请问现在送审到多少号啦？我是7434<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=31, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231206/2dee05e08ca84fb09f8330013e8e418e/e2624ef6b4474dc8bf92c7e3eed5d474.jpg, createdBy=4de09089222, createdName=ms5000001058303842, createdTime=Tue Dec 05 09:17:45 CST 2023, time=2023-12-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2190215, encodeId=174121902152a, content=uu们，请问2024.1.14号投的稿子，到现在一直是 Transfer Pending过去了这么久了，是不是要被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231207/d8ac6ae0bc4f46eb96530f032af93ce5/c7bf7aa943884522a9b566a5d00e8e79.jpg, createdBy=8beb8373299, createdName=是周树人非鲁迅, createdTime=Thu Feb 29 22:28:30 CST 2024, time=2024-02-29, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2187626, encodeId=3721218e626e6, content=投稿命中率:50.0 偏重的研究方向：乳酸化修饰;胃癌 经验分享：记录一下：2024年2月14 Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11f06507596, createdName=ms9000001327347856, createdTime=Fri Feb 16 10:32:22 CST 2024, time=2024-02-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2187904, encodeId=fb10218e90466, content=偏重的研究方向：肿瘤;干细胞 经验分享：小tips：这个期刊极其喜欢建议转投爱思唯尔旗下的bbr和hy两本杂志。千万千万别转投，这是为了提高这两本杂志投稿率才建议你转投的。转投一不会优先审稿二仍然需要自己网站操作。最难绷的是拒稿也很慢。。。拖拖拉拉一到两个月给你拒掉。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca8184855, createdName=ms6000000187674201, createdTime=Sun Feb 18 10:26:17 CST 2024, time=2024-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2110247, encodeId=e1b7211024e24, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：9天就接收了，从1月5号提交到1月14号，直接接收。这速度，神了，不禁感叹，神刊！！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bc56291844, createdName=3709443_9392, createdTime=Sat Jan 14 22:35:24 CST 2023, time=2023-01-14, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2153304, encodeId=b34c21533047f, content=请教各位，under review 快三周了，时间一直在变，但状态没变，这是什么情况有小伙伴知道不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b215411313, createdName=ms1000001079311439, createdTime=Thu Aug 17 21:43:03 CST 2023, time=2023-08-17, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2152251, encodeId=57672152251aa, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：分享一下投稿经验：7.25号Submitted to journal，7.28 内审，8.3 送外审，可以在**中跟踪到有多少审稿人，也可以看到有没有审稿人返稿，目前8月11日还没有审稿人返稿，等待后续，投的article。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6faa8350887, createdName=ms7000001902667042, createdTime=Fri Aug 11 12:45:13 CST 2023, time=2023-08-11, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2170081, encodeId=a92721e00814e, content=偏重的研究方向：microRNA 经验分享：稿件7186，润色提交，WB整膜三重复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd069039656, createdName=ms6000000198285398, createdTime=Tue Nov 21 21:51:38 CST 2023, time=2023-11-21, status=1, ipAttribution=贵州省)]

2023-08-11 ms7000001902667042 来自广东省

审稿速度:1.0 | 投稿命中率:75.0
经验分享：分享一下投稿经验：7.25号Submitted to journal，7.28 内审，8.3 送外审，可以在**中跟踪到有多少审稿人，也可以看到有没有审稿人返稿，目前8月11日还没有审稿人返稿，等待后续，投的article。

80 12

展开12条回复

[GetPortalCommentsPageByObjectIdResponse(id=590238, encodeId=8fae5902380a, content=24小时内接受了，果然是神刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=261, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0f52242192, createdName=12147f1dm17暂无昵称, createdTime=Tue May 05 00:00:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2188537, encodeId=4158218853e31, content=2024年2.18号晚上投稿，2.19号凌晨状态为submitted to journal，今天2.21号还是submitted to journal状态，编号为24-1364，希望能有个好结果吧，祈祷能赶上毕业！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73869177223, createdName=ms3000000806055068, createdTime=Wed Feb 21 17:36:20 CST 2024, time=2024-02-21, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2172975, encodeId=bbb521e297532, content=偏重的研究方向：分子生物学 经验分享：请问现在送审到多少号啦？我是7434<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=31, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231206/2dee05e08ca84fb09f8330013e8e418e/e2624ef6b4474dc8bf92c7e3eed5d474.jpg, createdBy=4de09089222, createdName=ms5000001058303842, createdTime=Tue Dec 05 09:17:45 CST 2023, time=2023-12-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2190215, encodeId=174121902152a, content=uu们，请问2024.1.14号投的稿子，到现在一直是 Transfer Pending过去了这么久了，是不是要被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231207/d8ac6ae0bc4f46eb96530f032af93ce5/c7bf7aa943884522a9b566a5d00e8e79.jpg, createdBy=8beb8373299, createdName=是周树人非鲁迅, createdTime=Thu Feb 29 22:28:30 CST 2024, time=2024-02-29, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2187626, encodeId=3721218e626e6, content=投稿命中率:50.0 偏重的研究方向：乳酸化修饰;胃癌 经验分享：记录一下：2024年2月14 Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11f06507596, createdName=ms9000001327347856, createdTime=Fri Feb 16 10:32:22 CST 2024, time=2024-02-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2187904, encodeId=fb10218e90466, content=偏重的研究方向：肿瘤;干细胞 经验分享：小tips：这个期刊极其喜欢建议转投爱思唯尔旗下的bbr和hy两本杂志。千万千万别转投，这是为了提高这两本杂志投稿率才建议你转投的。转投一不会优先审稿二仍然需要自己网站操作。最难绷的是拒稿也很慢。。。拖拖拉拉一到两个月给你拒掉。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca8184855, createdName=ms6000000187674201, createdTime=Sun Feb 18 10:26:17 CST 2024, time=2024-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2110247, encodeId=e1b7211024e24, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：9天就接收了，从1月5号提交到1月14号，直接接收。这速度，神了，不禁感叹，神刊！！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bc56291844, createdName=3709443_9392, createdTime=Sat Jan 14 22:35:24 CST 2023, time=2023-01-14, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2153304, encodeId=b34c21533047f, content=请教各位，under review 快三周了，时间一直在变，但状态没变，这是什么情况有小伙伴知道不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b215411313, createdName=ms1000001079311439, createdTime=Thu Aug 17 21:43:03 CST 2023, time=2023-08-17, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2152251, encodeId=57672152251aa, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：分享一下投稿经验：7.25号Submitted to journal，7.28 内审，8.3 送外审，可以在**中跟踪到有多少审稿人，也可以看到有没有审稿人返稿，目前8月11日还没有审稿人返稿，等待后续，投的article。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6faa8350887, createdName=ms7000001902667042, createdTime=Fri Aug 11 12:45:13 CST 2023, time=2023-08-11, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2170081, encodeId=a92721e00814e, content=偏重的研究方向：microRNA 经验分享：稿件7186，润色提交，WB整膜三重复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd069039656, createdName=ms6000000198285398, createdTime=Tue Nov 21 21:51:38 CST 2023, time=2023-11-21, status=1, ipAttribution=贵州省)]

2023-11-21 ms6000000198285398 来自贵州省

偏重的研究方向：microRNA
经验分享：稿件7186，润色提交，WB整膜三重复

80 5

展开5条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务